Clinical Scorecard: Functional Outcomes of Current Dry AMD Therapies
At a Glance
| Category | Detail |
|---|---|
| Condition | |
| Key Mechanisms | Dysregulation of the complement system, particularly the alternative pathway, leading to inflammation and geographic atrophy (GA). |
| Target Population | |
| Care Setting |
Key Highlights
- Visual function benefits from these treatments remain uncertain despite reductions in GA growth.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Regularly evaluate GA lesion growth and visual function using microperimetry and other assessments, including monocular reading speed.
Risks
Patient & Prescribing Data
Both pegcetacoplan and avacincaptad pegol target complement pathways to slow GA progression, but their impact on visual function is still under investigation, with ongoing studies assessing long-term outcomes.
Clinical Best Practices
- Engage patients in discussions about the potential benefits and limitations of current therapies, emphasizing the importance of understanding treatment limitations.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.